FRIDAY, July 20 (Healthday News) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration said Friday. read more..
 |
| A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel |
ZURICH (Reuters) - Novartis drug Afinitor, expected to become a major seller for the Swiss drugmaker, was approved by European regulators to treat women with a certain type of breast cancer, the company said on Monday. The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment. ... read more..
FRIDAY, April 27 (Healthday News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food And Drug Administration to treat benign kidney tumors among people with a rare genetic condition called tuberous sclerosis complex (TSC), the agency said in a news release. read more..
